MFX Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
42
- Latest Deal Type
-
Later Stage VC
- Investors
-
15
MFX General Information
Description
Operator of a cell therapy research and manufacturing platform designed to make bio-processing scalable and affordable for cell and gene therapy. The company's platform specializes in tackling the problems of process control and scalability with cell bioprocessing in particular for autologous cell and gene therapy, enabling biologists to carry out process development by running cell culture conditions in parallel with extreme process control and to scale up cells for manufacturing at a lower cost.
Contact Information
Website
www.mfx.bioCorporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road
- Stevenage SG1 2FX
- England, United Kingdom
Corporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road
- Stevenage SG1 2FX
- England, United Kingdom
MFX Timeline
MFX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC | 01-Jan-2026 | Completed | Generating Revenue | |||
| 13. Accelerator/Incubator | 01-Jun-2025 | Completed | Product In Beta Test | |||
| 12. Accelerator/Incubator | 01-Jan-2024 | Completed | Product In Beta Test | |||
| 11. Later Stage VC | 03-Sep-2024 | Completed | Product In Beta Test | |||
| 10. Grant | 19-Dec-2023 | Completed | Product In Beta Test | |||
| 9. Early Stage VC | 10-Oct-2023 | Completed | Product In Beta Test | |||
| 8. Secondary Transaction - Private | 01-Dec-2022 | Completed | Product In Beta Test | |||
| 7. Early Stage VC | 06-Apr-2022 | Completed | Startup | |||
| 6. Grant | 11-Jan-2022 | $1.5M | $1.78M | Completed | Startup | |
| 5. Secondary Transaction - Private | 01-Mar-2021 | $1.78M | Completed | Startup |
MFX Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferance Shares | ||||||||
| Ordinary | ||||||||
| Preferance Shares | ||||||||
| Ordinary | 968 | $0.012278 | $251.9 | $251.9 | 1x | $251.9 | 1.54% | |
| Ordinary | 22,360 | $0.012278 | $78.83 | $78.83 | 1x | $78.83 | 35.53% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MFX Patents
MFX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025233627-A2 | Systems and methods for bioprocessing | Pending | 10-May-2024 | ||
| WO-2025233627-A3 | Systems and methods for bioprocessing | Pending | 10-May-2024 | ||
| WO-2024246545-A1 | Microfluidic chip and system for bioprocessing and method of use thereof | Inactive | 31-May-2023 | ||
| WO-2024153916-A2 | Systems and methods for aseptic connection | Inactive | 16-Jan-2023 | ||
| WO-2024153916-A3 | Systems and methods for aseptic connection | Inactive | 16-Jan-2023 | C12M37/00 |
MFX Signals
MFX Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Southern Angel Investors Club | Angel Group | Minority | ||
| BioIndustry Association | Accelerator/Incubator | Minority | ||
| Grow London | Accelerator/Incubator | |||
| AT8 Capital Partners | Venture Capital | Minority | ||
| Esco Lifesciences Group | VC-Backed Company | Minority |
MFX FAQs
-
When was MFX founded?
MFX was founded in 2018.
-
Where is MFX headquartered?
MFX is headquartered in Stevenage, United Kingdom.
-
What is the size of MFX?
MFX has 42 total employees.
-
What industry is MFX in?
MFX’s primary industry is Discovery Tools (Healthcare).
-
Is MFX a private or public company?
MFX is a Private company.
-
What is MFX’s current revenue?
The current revenue for MFX is .
-
How much funding has MFX raised over time?
MFX has raised $19.3M.
-
Who are MFX’s investors?
Southern Angel Investors Club, BioIndustry Association, Grow London, AT8 Capital Partners, and Esco Lifesciences Group are 5 of 15 investors who have invested in MFX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process